Sign Up to like & get
recommendations!
3
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6702
Abstract: Background: The Blood First Assay Screening Trial (BFAST) (NCT03178552) is a prospective study screening for actionable genetic alterations using NGS of ctDNA among patients with treatment-naive advanced or metastatic NSCLC. We aimed to perform a…
read more here.
Keywords:
ctdna assay;
genomic alterations;
blood based;
based ngs ... See more keywords